YU51903A - Enolati inhibitora izmene natrijum-vodonik tipa-1 - Google Patents

Enolati inhibitora izmene natrijum-vodonik tipa-1

Info

Publication number
YU51903A
YU51903A YU51903A YUP51903A YU51903A YU 51903 A YU51903 A YU 51903A YU 51903 A YU51903 A YU 51903A YU P51903 A YUP51903 A YU P51903A YU 51903 A YU51903 A YU 51903A
Authority
YU
Yugoslavia
Prior art keywords
ethanolates
inhibitor
sodium
exchanger type
hydrogen exchanger
Prior art date
Application number
YU51903A
Other languages
English (en)
Inventor
Timothy Norris
Rodney Matthew Weekly
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU51903A publication Critical patent/YU51903A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Pronalazak se odnosi na enolate NHE-1 inhibitora, N-(5-ciklopropil-1-hinolin-5-il 1H-pirazol-4-karbonil)-gvanidina, kristalne oblike etanolata, postupke dobijanja etanolata, postupke lečenja polazeći od etanolata i metilsulfonatne soli NHE-1 inhibitora dobijenog od etanolata.[The invention relates to ethanolates of the NHE-1 inhibitor, N-(5-cyclopropyl-1-quinolin-5-yl-1H-pyrazole-4-carbonyl)-guanidine, crystalline forms of the ethanolates, methods of preparing the ethalolates, methods of treatment using the ethanolates and the mesylate salt of the NHE-1 inhibitor prepared using the ethanolates.
YU51903A 2001-01-31 2001-12-21 Enolati inhibitora izmene natrijum-vodonik tipa-1 YU51903A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26545601P 2001-01-31 2001-01-31

Publications (1)

Publication Number Publication Date
YU51903A true YU51903A (sh) 2006-05-25

Family

ID=23010519

Family Applications (1)

Application Number Title Priority Date Filing Date
YU51903A YU51903A (sh) 2001-01-31 2001-12-21 Enolati inhibitora izmene natrijum-vodonik tipa-1

Country Status (17)

Country Link
US (1) US20020147218A1 (sh)
EP (1) EP1355899A1 (sh)
JP (1) JP2004518686A (sh)
KR (1) KR20030069228A (sh)
CN (1) CN1479737A (sh)
AR (1) AR035740A1 (sh)
BR (1) BR0116841A (sh)
CA (1) CA2436539A1 (sh)
CZ (1) CZ20032017A3 (sh)
HU (1) HUP0302860A2 (sh)
IL (1) IL156220A0 (sh)
MX (1) MXPA03006872A (sh)
PL (1) PL363472A1 (sh)
RU (1) RU2242472C1 (sh)
WO (1) WO2002060892A1 (sh)
YU (1) YU51903A (sh)
ZA (1) ZA200303891B (sh)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454902A1 (en) * 1998-02-27 2004-09-08 Pfizer Products Inc. N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia
US6441176B1 (en) * 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
UA72002C2 (en) * 1999-10-29 2005-01-17 Pfizer Prod Inc Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage
EA004882B1 (ru) * 2000-04-28 2004-08-26 Пфайзер Продактс Инк. Ингибитор натрий-водородного обмена типа 1(nhe-1)

Also Published As

Publication number Publication date
CA2436539A1 (en) 2002-08-08
WO2002060892A8 (en) 2003-07-31
RU2003123792A (ru) 2005-01-20
IL156220A0 (en) 2003-12-23
JP2004518686A (ja) 2004-06-24
EP1355899A1 (en) 2003-10-29
ZA200303891B (en) 2004-05-20
AR035740A1 (es) 2004-07-07
US20020147218A1 (en) 2002-10-10
WO2002060892A1 (en) 2002-08-08
RU2242472C1 (ru) 2004-12-20
PL363472A1 (en) 2004-11-15
CZ20032017A3 (cs) 2004-05-12
BR0116841A (pt) 2004-02-25
CN1479737A (zh) 2004-03-03
HUP0302860A2 (hu) 2003-12-29
MXPA03006872A (es) 2003-11-13
KR20030069228A (ko) 2003-08-25

Similar Documents

Publication Publication Date Title
NO20005454D0 (no) Nye hydroksyindoler, deres anvendelse som fosfodiesterase 4 inhibitorer og fremgangsmÕte for fremstilling derav
CY1108808T1 (el) Ενωσεις μοτιλιδης
NO20051082L (no) Antimikrobielle kinoloner, deres sammensetninger og anvendelser
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
TW200615264A (en) N-(ortho-phenyl)-1-methyl-3-difluoromethylpyrazole-4-carboxanilides and their use as fungicides
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
NO20005264L (no) Heterocyklisk substituerte amider, deres fremstilling og anvendelse
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
DK1446380T3 (da) Formoteroltartrafremgangsmåde og polymorf
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DE69936285D1 (de) INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
DK1068223T3 (da) Lipopeptidantibiotika-calciumsalte, fremgangsmåde til deres fremstilling og anvendelse
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
DK1307237T3 (da) Perfluoralkylholdige komplekser med polære grupper, fremgangsmåde til fremstilling og anvendelse heraf
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
YU51903A (sh) Enolati inhibitora izmene natrijum-vodonik tipa-1
NO20021950D0 (no) Fremgangsmåte for fremstilling av N-(4,5-bis-metansulfonyl-2- metylbenzoyl)-guanidin-hydroklorid
MY136854A (en) Crystalline n-formyl hydroxylamine compounds
MXPA04004685A (es) Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno.
NO20033965D0 (no) Caloporosidderivater, fremgangsmåte for deres fremstilling og deres anvendelse
NO20040426L (no) Nye imidazolidinderivater og deres fremstilling og andvendelse som VLA-4-antagonister.
NO20022844D0 (no) N-(1-fenyletyl)-5-fenyl-imidazol-2-aminforbindelser, deres sammensetninger og anvendelser